Almirall, S.A., the global pharmaceutical company based in Barcelona, will continue to rely on legal channels to defend itself against Viveve’s patent infringement suit, after having been notified of the denial by the District Court for the Eastern District of Texas of ThermiGen, LLC's motions to dismiss the Viveve suit. The decision specifically confirms that the lawsuit has no effect on physicians offering the ThermiVa procedure in their practices.
Almirall, S.A., the global pharmaceutical company based in Barcelona, announced today the appointment of Vladimir Paul-Blanc to the position of President & General Manager of ThermiGen, LLC, starting May 1st. He will report directly to the Executive Vice-president of Commercial Strategy of Almirall, Alfonso Ugarte, and he will be responsible for all general management responsibilities for the Thermi business globally. He will also be in charge of driving the company's achievement of short and long term revenues and profitability goals through global operations, marketing, sales, and coordination of business development activities.